Nasus Pharma opened lower at $2.90, compared with its previous close of $2.91. In the last trading session, the stock traded between $2.76 and $2.91. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Nasus Pharma is now worth
$ 33.79
Resulting in a loss of
$ 66.21 (66.21%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.12 (-4.19%)
Day High
$2.91
Day Low
$2.76
Day Open
$2.90
Prev Close
$2.91
Volume
8,357
1W Return
-5.33%
1M Return
-16.28%
3M Return
-14.40%
6M Return
-8.29%
1Y Return
-63.27%
Fundamentals
Market Cap ($ Mn)
33
PE Ratio
-
PB Ratio
4.37
PEG Ratio
-
ROE
-
ROCE
376.71%
EPS (TTM)
-
Investment Returns
1 Week
-5.33%
1 Month
-16.28%
3 Months
-14.40%
6 Months
-8.29%
9 Months
-50.21%
Financials
Quarterly
All values in $ Mn
No data available.
Updates
30Oct
Maxim Group initiates Nasus Pharma with Buy rating, $7 target
Maxim Group analyst Naz Rahman initiated coverage on Nasus Pharma. The firm assigned a Buy rating to the stock. A price target of $7 was announced by the analyst. Nasus Pharma is listed on the AMEX exchange.
13 days ago
8Sep
Nasus Pharma to present at H.C. Wainwright investment conference
Nasus Pharma management to present at H.C. Wainwright conference in New York. Event runs from September 14-16, 2026, with on-demand access available. CEO Brendan O’Grady and CFO Eyal Rubin will meet with investors. Company focuses on intranasal therapies, led by anaphylaxis candidate NS002.
2mo ago
19Aug
Nasus Pharma CFO Eyal Rubin to Depart; Elmaliach Named Interim
Nasus Pharma Ltd (NYSE: NSRX) disclosed that CFO Eyal Rubin will resign effective September 18, 2026, to join a sector outside life sciences. Director of Finance Oren Elmaliach, who has been with the firm since inception, assumes the role of interim CFO. The leadership change aims to maintain operational continuity as the biopharmaceutical company advances its lead candidate NS002.
Nasus Pharma's H1FY26 EPS of $(0.54) missed estimates by 170%, reflecting a 354% widening in net loss to $5.9 million. Rising R&D and G&A costs drove the expense surge, though a $15 million private placement boosted cash reserves to $11.9 million, providing runway into mid-2027.
2mo ago
28Jul
Nasus Pharma appoints Brendan O'Grady as CEO
Nasus Pharma Ltd. appoints Brendan P. O'Grady as CEO, effective July 27, 2026, succeeding Dan Teleman. O'Grady will focus on commercializing NS002 and advancing the Nasax® technology platform.
